Oxyresveratrol attenuates bone resorption by inhibiting the mitogen-activated protein kinase pathway in ovariectomized rats.
Background: Bone is continuously produced by osteoblasts and resorbed by osteoclasts to maintain homeostasis. Impaired bone resorption by osteoclasts causes bone diseases such as osteoporosis and arthritis. Most pharmacological treatment of osteoporosis focuses on inhibiting osteoclast differentiati...
| Publicado en: | Nutrition & Metabolism Vol. 21; no. 1; pp. 1 - 14 |
|---|---|
| Autores principales: | , , |
| Formato: | diagnostic images pictorial research tables/charts Journal Article |
| Publicado: |
BioMed Central
1/19/2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174917367&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 174917367 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17437075 1CYX jtl: Nutrition & Metabolism issn: 17437075 maglogo: N pubinfo: dt: 1/19/2024 vid: 21 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 174917367 174917367 174917367 10.1186/s12986-024-00781-4 174917367 ppf: 1 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Oxyresveratrol attenuates bone resorption by inhibiting the mitogen-activated protein kinase pathway in ovariectomized rats. aug: au: Lee, Yea-Jin Ahn, Jin-Chul Oh, Chung-Hun affil: https://ror.org/058pdbn81 Department of Medicine, Dankook University, 31116, Cheonan-si, Republic of Korea sug: subj: Osteoporosis Prevention and Control Bone Resorption Drug Therapy Stilbenes Pharmacodynamics Polyphenols Pharmacodynamics Bone Resorption Drug Effects Signal Transduction Drug Effects Bone Density Drug Effects Osteoclasts Drug Effects Cell Differentiation Drug Effects Oophorectomy Animal Studies Rats Molecular Structure Macrophages Drug Effects Osteoblasts Models, Biological Staining and Labeling RNA, Messenger Analysis Gene Expression Drug Effects Pyridines Urine Tomography, X-Ray Computed Methods NF-kappa B Drug Effects Phosphorylation Drug Effects Extracellular Space Drug Effects Transcription Factors Drug Effects Peptide Hydrolases Drug Effects Funding Source ab: Background: Bone is continuously produced by osteoblasts and resorbed by osteoclasts to maintain homeostasis. Impaired bone resorption by osteoclasts causes bone diseases such as osteoporosis and arthritis. Most pharmacological treatment of osteoporosis focuses on inhibiting osteoclast differentiation, often to restore osteoclast/osteoclast balance. However, recent osteoporosis treatments have various side effects. According to a recent study, resveratrol, known as a stilbenoid family, is known to increase bone density, and the osteoclast inhibitory effect was confirmed using oxyresveratrol, a stilbenoid family. Here, we investigated the effect of oxyresveratrol on osteoclast differentiation and an ovariectomized mouse model. Methods: Mouse leukemia monocyte/macrophage cell line RAW 264.7 was treated with oxyresveratrol, and cell cytotoxicity was confirmed by measuring MTT assay. Tartrate-resistant acid phosphatase (TRAP), an enzyme marker for osteoclasts, was confirmed by staining. In addition, osteoclast differentiation markers and MAPK-related markers were confirmed at the mRNA level and protein expression. The effect of oxyresveratrol was confirmed using ovariectomized mice. Deoxypyridinoline (DPD) was measured using mouse urine and TRAP activity was observed using serum. Bone mineral density was also measured using Micro-CT. Results: The polyphenol oxyresveratrol inhibited receptor activator of nuclear factor kappa-Β ligand (RANKL)-induced osteoclast differentiation of RAW 264.7 cells. Furthermore, oxyresveratrol inhibited TRAP activity and actin-ring formation. Moreover, oxyresveratrol suppressed the phosphorylation of the RANKL-induced mitogen-activated protein kinases (MAPKs) p38, JNK, and ERK and significantly reduced the expression of bone differentiation markers (NFATc1, cathepsin K, and TRAP). Conclusion: Oxyresveratrol inhibits osteoclast differentiation via MAPK and increases bone density in ovariectomized rats, suggesting it has therapeutic potential for bone diseases such as osteoporosis. We confirmed the osteoporosis prevention effect of OR in Raw 264.7 cells, and future studies should confirm the effect of OR using rat bone marrow-derived cells. pubtype: Academic Journal doctype: diagnostic images pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|